Next Article in Journal
Lipidation of Pneumococcal Antigens Leads to Improved Immunogenicity and Protection
Next Article in Special Issue
Immunoinformatic Analysis of T- and B-Cell Epitopes for SARS-CoV-2 Vaccine Design
Previous Article in Journal
The Survivor: A Clinical Case of Tetanus in a Non-Immunized, Parenteral Drug User, Former Female Convict with HIV and HCV
Previous Article in Special Issue
Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2
Open AccessReview

Vaccines against Coronaviruses: The State of the Art

Pediatric Clinic, Department of Medicine and Surgery, Pietro Barilla Children’s Hospital, University of Parma, 43126 Parma, Italy
Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy
Author to whom correspondence should be addressed.
Vaccines 2020, 8(2), 309;
Received: 29 May 2020 / Revised: 12 June 2020 / Accepted: 15 June 2020 / Published: 17 June 2020
The emerging epidemic caused by the new coronavirus SARS-CoV-2 represents the most important socio-health threat of the 21st century. The high contagiousness of the virus, the strong impact on the health system of the various countries and the absence to date of treatments able to improve the prognosis of the disease make the introduction of a vaccine indispensable, even though there are currently no approved human coronavirus vaccines. The aim of the study is to carry out a review of the medical literature concerning vaccine candidates for the main coronaviruses responsible for human epidemics, including recent advances in the development of a vaccine against COVID-19. This extensive review carried out on the vaccine candidates of the main epidemic coronaviruses of the past has shown that the studies in animal models suggest a high efficacy of potential vaccines in providing protection against viral challenges. Similar human studies have not yet been carried out, as the main trials are aimed at assessing mainly vaccine safety and immunogenicity. Whereas the severe acute respiratory syndrome (SARS-CoV) epidemic ended almost two decades ago and the Middle East respiratory syndrome (MERS-CoV) epidemic is now better controlled, as it is less contagious due to the high lethality of the virus, the current SARS-CoV-2 pandemic represents a problem that is certainly more compelling, which pushes us to accelerate the studies not only for the production of vaccines but also for innovative pharmacological treatments. SARS-CoV-2 vaccines might come too late to affect the first wave of this pandemic, but they might be useful if additional subsequent waves occur or in a post-pandemic perspective in which the virus continues to circulate as a seasonal virus. View Full-Text
Keywords: coronavirus; MERS; pandemic; SARS; SARS-CoV-2; vaccine candidate coronavirus; MERS; pandemic; SARS; SARS-CoV-2; vaccine candidate
MDPI and ACS Style

Conte, C.; Sogni, F.; Affanni, P.; Veronesi, L.; Argentiero, A.; Esposito, S. Vaccines against Coronaviruses: The State of the Art. Vaccines 2020, 8, 309.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop